To our knowledge, LEADER is the first prospective clinical trial to directly investigate a) 600 mg intermittent vs 400 mg continuous ribociclib and b) early vs delayed start of ribociclib in combination with adjuvant ET for patients with localized HR+/HER2– breast cancer, with a duration of 12 months. This evidence concerns the gene ERBB2 and breast carcinoma.